Navigation Links
Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
Date:8/8/2012

THOUSAND OAKS, Calif., Aug. 8, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA  (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.  Based on the review of a pre-planned interim analysis, the DMC concluded that the addition of ganitumab to gemcitabine is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared to gemcitabine alone. There were no safety concerns raised in the DMC review of the study. 

The GAMMA study is a randomized, multicenter, double-blind, Phase 3 trial to determine if ganitumab plus gemcitabine improves overall survival, compared to placebo plus gemcitabine, in the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.   

"These disappointing results underscore the difficulty of treating pancreatic cancer, which remains a major unmet medical need," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We would like to thank the patients, caregivers and investigators for their participation and engagement in the study."

Amgen has communicated with regulatory authorities and is in the process of notifying study investigators that treatment with ganitumab should be discontinued in the GAMMA trial, as well as a separate ongoing Phase 2 trial in locally advanced pancreatic cancer.

Ganitumab is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF1R).

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
2. Amgen Completes Acquisition of KAI Pharmaceuticals
3. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
4. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
7. Amgen to Present at the Baird Growth Stock Conference
8. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
9. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
10. AHM Announces New SVP Product Delivery
11. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014   Zacks Equity Research highlights Epizyme ... the Day and Panera (Nasdaq: PNRA - Free Report ) ... provides analysis on Amicus Therapeutics (Nasdaq: FOLD - Free Report ... (Nasdaq: SHPG - Free Report ). Here is ... of the Day : The biotech bull market ...
(Date:8/22/2014)... Research and Markets has announced the addition ... Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... a focus on the Chinese situation. The report ... classifications, applications and industry chain structure. The particulate respirators ...
(Date:8/22/2014)... , Cali ., Aug. 22, 2014 ... Papillomavirus Conference shows that a therapy being developed by Hera ... two that cause 70 percent of all cervical cancer. ... blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according ... Broker , Ph.D., who presented the findings at the ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Global and Chinese Particulate Respirators Industry Report 2014 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... DIEGO, Jan. 31, 2011 Volcano Corporation (Nasdaq: ... of Massachusetts has issued a decision that ruled in ... Inc., and against LightLab Imaging, Inc., on all of ... 11-page decision also rejected LightLab,s request for injunctive relief. ...
... its continuing partnerships with Brazilian public health authorities and ... Mr. Nelson dos Santos as interim vice president of ... nonprofit organization whose mission is to improve the health ... programs that help ensure the quality, safety and benefit ...
Cached Medicine Technology:Massachusetts Court Rules in Favor of Volcano and Against St. Jude Medical Subsidiary in Trade Secrets Case 2New Interim Leadership for USP-Brazil 2
(Date:8/22/2014)... 265,000 Danes are acutely admitted to medical departments with ... and Aarhus University Hospital now shows that many of ... are sent home again without receiving a diagnosis of ... "Naturally, there is no need for a diagnosis if ... a serious illness. So some patients will always be ...
(Date:8/22/2014)... nurses at New York University,s Langone Medical Center (NYULMC) ... the youngest and most vulnerable down flights of stairs ... generated by Hurricane Sandy. , Now, a recent ... of Nursing (NYUCN) and of Dentistry (NYUCD), published in ... impact on NYULMC nurses, post-Sandy deployment to help address ...
(Date:8/22/2014)... August 22, 2014 Human induced pluripotent ... of regenerative medicine because they can be coaxed to ... always act as anticipated. They sometimes mutate, develop into ... a new study recently published in STEM CELLS Translational ... this, simply by removing the material used to reprogram ...
(Date:8/22/2014)... low levels of nicotine may reduce addiction without ... new study from the University of Waterloo. ... Cancer Epidemiology monitored the smoking behaviours of ... of cigarettes with markedly reduced nicotine levels. , ... of which have very similar levels of nicotine ...
(Date:8/22/2014)... 2014 Lincolnshire Marriott Resort is inviting ... a tap, announcing Marriott’s new iPad Mini promotion for ... this exclusive offer will receive a complimentary iPad Mini ... the day’s agenda with ease. Marriott’s Meeting Services app, ... and connect with their group with just a few ...
Breaking Medicine News(10 mins):Health News:Many patients are discharged without a diagnosis 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 3Health News:Removing Programming Material After Inducing Stem Cells Could Improve Their Regeneration Ability 2Health News:Smokers consume same amount of cigarettes regardless of nicotine levels 2Health News:Lincolnshire Marriott Resort Offers iPad Mini for Chicago Meeting Planners 2
... Oct. 5 "The good news is,that there ... Terry D. Hashey,Medical Director of First Coast Family ... Corral Flu Campaign. "The bad news,is that despite ... still,ranked below the national average of 69.3% for ...
... dietary supplement ... LipidShield Plus(TM), MELBOURNE, Fla., Oct. ... has expanded again and LipidShield Plus(TM) is,now available at Stop & ... breakthrough cholesterol,fighting product that has been clinically proven to lower cholesterol ...
... Oct. 5 /Xinhua-PRNewswire/ -- In a star-studded ... Olympics honored twelve,extraordinary individuals and the city ... made and continue to make to promote ... of people with intellectual,disabilities, and the Special ...
... SOUTH SAN FRANCISCO, Calif., Oct. 4 Sunesis,Pharmaceuticals, Inc. ... inducement stock options awards in accordance with NASDAQ,Marketplace Rule ... stock options cover an aggregate of 48,000 shares of,common ... an,exercise price equal to the fair market value of ...
... Calif., Oct. 4 The Integrated Healthcare,Association ... to physician,groups in California at its annual ... 47 most outstanding physician groups were,honored for ... care,quality measures, including preventive care and chronic ...
... HealthShares(TM) Inc., an investment,company with a series ... been informed by Standard & Poor,s, the calculating ... at the opening of,trading on October 8, 2007, ... (NasdaqGS: FOXH) in the,HealthShares(TM) Cardio Devices Index. ...
Cached Medicine News:Health News:Florida Health Care Community Stepping Up for the 2007-2008 Flu Season 2Health News:New Health Corp. Announces the Addition of Stop & Shop and Giant Supermarkets to its Retail Outlets 2Health News:Special Olympics 'Special Spirit in China Award Of Excellence' Presented to Dedicated Friends of Special Olympics and City of Shanghai 2Health News:Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2Health News:California Physician Groups Recognized by Integrated Healthcare Association (IHA) 2Health News:California Physician Groups Recognized by Integrated Healthcare Association (IHA) 3Health News:California Physician Groups Recognized by Integrated Healthcare Association (IHA) 4Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Cardio Devices Index 2Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Cardio Devices Index 3
... Novagen's Vacuum Manifold system for sample ... to which a vacuum is applied, a ... accessories for convenience in sample handling. The ... elution of up to 12 samples simultaneously. ...
For regulating sample flow rate when using the QIAvac 24 Plus;...
For processing mini spin columns on QIAvac 6S;...
For monitoring vacuum pressure, suitable for use with all QIAvac manifolds;...
Medicine Products: